Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
Clinical trial NCT05218499 · COMPLETED
Trial details
- NCT number
- NCT05218499
- Sponsor
- Boehringer Ingelheim
- Status
- COMPLETED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-31
- Primary completion
- 2024-04-16
- Enrollment
- 400
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.